Histone Deacetylase Inhibitors and Epigenetic Modifications As a Novel Strategy in Renal Cell Carcinoma

Overview

Journal Cancer J

Specialty Oncology

Date 2013 Jul 23

PMID 23867515

Citations 16

Authors

Swathi Ramakrishnan

Roberto Pili

Affiliations

Soon will be listed here.

Abstract

Recent investigations of renal cell carcinoma (RCC) have revealed several epigenetic modifications, as well as alterations in the genes and enzymes that regulate these changes. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play a critical role in RCC tumorigenesis. Specific changes in DNA methylation and mutations of histone modifiers have been identified and may be associated with an aggressive phenotype. In addition, the potential of reversing the effects of these enzymes and hence reversing the cellular epigenetic landscape to a "normal phenotype" have led to an increasing interest in developing targeted chromatin remodeling agents. However, the translation of the understanding of these changes to the clinic for the treatment of RCC has posed significant challenges, partly due to tumor heterogeneity. This review describes the aberrant histone and DNA alterations recently reported in RCC and highlights the potential targeted chromatin remodeling therapies in the management of this disease.

Citing Articles

PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: with the involvement of the HDAC3/microRNA-195-5p/SGK1.

Liu S, Chen L, Chen P, Huang M, Liu T, Peng J Clin Epigenetics. 2022; 14(1):131.

PMID: 36266728 PMC: 9583501. DOI: 10.1186/s13148-022-01336-1.

Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Lesko P, Chovanec M, Mego M Nat Rev Urol. 2022; 19(11):637-658.

PMID: 36028719 DOI: 10.1038/s41585-022-00624-y.

HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells.

Namwan N, Senawong G, Phaosiri C, Kumboonma P, Somsakeesit L, Samankul A Molecules. 2022; 27(13).

PMID: 35807258 PMC: 9268269. DOI: 10.3390/molecules27134014.

The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker.

Ordog N, Borsos B, Majoros H, Ujfaludi Z, Pankotai-Bodo G, Banko S Transl Oncol. 2022; 20:101420.

PMID: 35417813 PMC: 9018449. DOI: 10.1016/j.tranon.2022.101420.

Comprehensive analysis of a new prognosis signature based on histone deacetylases in clear cell renal cell carcinoma.

Cheng F, Zheng B, Wang J, Zhao G, Yao Z, Niu Z Cancer Med. 2021; 10(18):6503-6514.

PMID: 34308568 PMC: 8446567. DOI: 10.1002/cam4.4156.

References

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

Verheul H, Salumbides B, van Erp K, Hammers H, Qian D, Sanni T . Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008; 14(11):3589-97. DOI: 10.1158/1078-0432.CCR-07-4306. View

Tsai H, Baylin S . Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011; 21(3):502-17. PMC: 3193419. DOI: 10.1038/cr.2011.24. View

Waldmann T, Schneider R . Targeting histone modifications--epigenetics in cancer. Curr Opin Cell Biol. 2013; 25(2):184-9. DOI: 10.1016/j.ceb.2013.01.001. View

Juengel E, Engler J, Mickuckyte A, Jones J, Hudak L, Jonas D . Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int. 2009; 105(4):549-57. DOI: 10.1111/j.1464-410X.2009.08759.x. View

You J, Jones P . Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell. 2012; 22(1):9-20. PMC: 3396881. DOI: 10.1016/j.ccr.2012.06.008. View

Morris M, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T . Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer. 2008; 98(2):496-501. PMC: 2361461. DOI: 10.1038/sj.bjc.6604180. View

Wang X, Qian D, Ren M, Kato Y, Wei Y, Zhang L . Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res. 2005; 11(9):3535-42. DOI: 10.1158/1078-0432.CCR-04-1092. View

10.

Garcia-Manero G, Issa J . Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005; 23(7):635-42. DOI: 10.1080/07357900500283119. View

11.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni T . Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 2007; 13(15 Pt 1):4538-46. DOI: 10.1158/1078-0432.CCR-07-0014. View

12.

Sato A, Asano T, Ito K, Asano T . Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells. Urology. 2012; 79(4):966.e13-21. DOI: 10.1016/j.urology.2011.11.033. View

13.

Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D . Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med. 2008; 13(8B):2342-2352. PMC: 6529979. DOI: 10.1111/j.1582-4934.2008.00603.x. View

14.

Dong G, Luo J, Kumar V, Dong Z . Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol. 2009; 298(2):F293-300. PMC: 2822515. DOI: 10.1152/ajprenal.00410.2009. View

15.

Ying J, Poon F, Yu J, Geng H, Wong A, Qiu G . DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 2009; 100(4):663-9. PMC: 2653732. DOI: 10.1038/sj.bjc.6604888. View

16.

Gronbaek K, Hother C, Jones P . Epigenetic changes in cancer. APMIS. 2007; 115(10):1039-59. DOI: 10.1111/j.1600-0463.2007.apm_636.xml.x. View

17.

de Ruijter A, van Gennip A, Caron H, Kemp S, van Kuilenburg A . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2002; 370(Pt 3):737-49. PMC: 1223209. DOI: 10.1042/BJ20021321. View

18.

Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T . Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. Urology. 2010; 76(3):764.e7-13. DOI: 10.1016/j.urology.2010.04.042. View

19.

Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W . Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2002; 1(3):194-202. DOI: 10.1038/35106079. View

20.

Sato A, Asano T, Ito K, Sumitomo M, Asano T . Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int. 2011; 109(8):1258-68. DOI: 10.1111/j.1464-410X.2011.10533.x. View